These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17250462)

  • 1. Cetuximab in the treatment of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Expert Opin Biol Ther; 2007 Feb; 7(2):243-56. PubMed ID: 17250462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab for treatment of metastatic colorectal cancer.
    Cerea G; Ricotta R; Schiavetto I; Maugeri MR; Sartore-Bianchi A; Moroni M; Artale S; Siena S
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii66-7. PubMed ID: 16760297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
    [No Abstract]   [Full Text] [Related]  

  • 6. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer.
    Macarulla T; Ramos FJ; Elez E; Capdevila J; Peralta S; Tabernero J
    Clin Colorectal Cancer; 2008 Sep; 7(5):300-8. PubMed ID: 18794061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab: appraisal of a novel drug against colorectal cancer.
    Hildebrandt B; le Coutre P; Nicolaou A; Köble K; Riess H; Dörken B
    Recent Results Cancer Res; 2007; 176():135-43. PubMed ID: 17607921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab: from bench to bedside.
    Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
    Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in colon cancer.
    Giuliani F; Colucci G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S62-70. PubMed ID: 17520583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
    Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
    Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
    Hecht JR
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S15-21; quiz S22-4. PubMed ID: 18499885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
    Jackson C; Cunningham D
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab in metastatic colorectal cancer.
    Broadbridge VT; Karapetis CS; Price TJ
    Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.